Outcome of direct-acting antiviral treatment for patients with chronic hepatitis C virus infection: clinical benefit proven?

作     者：Raoel Maan Adriaan J.van der Meer Raoel Maan;Adriaan J.van der Meer

作者机构：Department of Gastroenterology and HepatologyErasmus MC University Medical Center RotterdamRotterdamthe Netherlands 

出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)

年 卷 期：2020年第9卷第2期

页      面：257-259页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100401[医学-流行病与卫生统计学] 10[医学] 

主　　题：patients infection clinical 

摘      要：The highly effective direct-acting antivirals(DAAs)for the treatment of chronic hepatitis C virus(HCV)infection were well-received by both patients and physicians as sustained virological response(SVR)was associated with an improved overall survival in patients with stable liver disease,even in case of cirrhosis(1).Yet,at that time these results were derived from retrospective cohort studies with long-term follow-up after interferon-based *** patients with compensated liver disease there is confidence that SVR is a clinically relevant endpoint based on consistent positive results with smart use of statistics in numerous cohort ***,however,there remains a need for long-term follow-up data showing a clinical benefit of DAA-induced SVR,preferably with high-quality prospective *** results from the French ANRS CO22 Hepather cohort,as published by *** and colleagues in the April issue of the Lancet,thus bring an important contribution to the field(2).It’s the first prospective cohort study with reasonable follow-up time to assess all-cause mortality after DAA therapy.